Literature DB >> 28602481

Three new abietane-type diterpene glycosides from the roots of Tripterygium wilfordii.

Jianqun Liu1, Qiushan Wu2, Jicheng Shu2, Rui Zhang2, Lifang Liu3.   

Abstract

Three new abietane-type diterpene glycosides named as tripterycoside A (1), tripterycoside B (2), tripterycoside C (3), along with two known ones, 11-O-β-d-glucopyranosyl-neotritophenolide (4), wilfordoside A (5), and nine other known compounds, 5-hydroxymethylmellein (6),1,2-bis-(3-methoxy-4-hydroxyphenyl)-1,3-propanediol (7), leptolepisol C (8), icariol A2 (9), tripfordine A (10), 16α-hydroxy-ent-kauran-19-oic acid (11),wilforine (12), wilfordine (13), 3-acetyloleanolic acid (14),were isolated from the roots of Tripterygium wilfordii. Their structures have been elucidated on the basis of NMR and MS data. To the best of our knowledge, abietane-type diterpene glycosides were rarely reported natural products, especially abietane-type diterpene glycoside containing 7-oxo group (compound 3) was reported here for the first time. Furthermore, compounds 6, 7, 8 and 14 were isolated from this plant for the first time. Compounds 1-5 showed statistically significant inhibitory effects on IL-1β secretion in LPS-induced rat primary synovial fibroblasts at 10μM.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Abietane diterpene glycoside; Tripterycoside B; Tripterycoside C; Tripterycoside a; Tripterygium wilfordii

Mesh:

Substances:

Year:  2017        PMID: 28602481     DOI: 10.1016/j.fitote.2017.06.001

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  1 in total

Review 1.  Activities and Molecular Mechanisms of Diterpenes, Diterpenoids, and Their Derivatives in Rheumatoid Arthritis.

Authors:  Muhammad Torequl Islam; Cristina Quispe; Jesús Herrera-Bravo; Md Mizanur Rahaman; Rajib Hossain; Chandan Sarkar; Md Abdur Raihan; Md Mashrur Chowdhury; Shaikh Jamal Uddin; Jamil A Shilpi; João Marcelo de Castro E Sousa; Ana Amélia de Carvalho Melo-Cavalcante; Mohammad S Mubarak; Javad Sharifi-Rad; Daniela Calina
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.